Prevalence, predictors, and emerging biomarkers for cognitive impairment and neuropsychiatric manifestations in Parkinson's disease in Africa: A systematic review.

Authors

Mundih Noelar Njohjam, Falonne Tiffany Niakam, Mark Olivier Ngoule

Published in

Journal of Parkinson's disease. Pages 1877718X261479269. Aug 14, 2026. Epub Aug 14, 2026.

Abstract

BackgroundCognitive impairment and neuropsychiatric manifestations are common disabling non-motor symptoms that can negatively impact quality of life in Parkinson's disease. This review aimed to critically appraise and synthesize evidence on the prevalence, predictors, and emerging biomarkers of cognitive impairment and neuropsychiatric manifestations among patients with Parkinson's disease in Africa.MethodsWe conducted a systematic review of studies reporting cognitive and neuropsychiatric outcomes among individuals with Parkinson's disease in African populations, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We used the Critical Appraisal Skills Program checklist to determine the quality of the included studies. The Grading of Recommendations, Assessment, Development, and Evaluation approach was used to estimate the certainty of the evidence.ResultsA total of 32 studies, including 3687 patients, were analyzed. The prevalence of cognitive impairment ranged from 21.6% to 92%. Depression was the most common neuropsychiatric symptom (up to 81.7%). Consistent predictors of cognitive impairment included older age, advanced disease, and greater motor severity. Importantly, APOE ε4 homozygosity was associated with a twofold increase in the risk of cognitive impairment, while findings on LRRK2 G2019S mutations were heterogeneous across populations. Additionally, hypocalcemia and retinal nerve fiber layer thinning were linked to worse cognitive outcomes. Functional neuroimaging studies revealed altered emotional processing, with enhanced activation of limbic and cortical networks in response to positive emotional stimuli.ConclusionsEvidence from this review suggests that cognitive impairment and neuropsychiatric manifestations are common in African PD populations and may be associated with clinical, genetic, metabolic, and neurobiological factors, although the quality of the evidence is low. Larger, community-based, and longitudinal studies are warranted.

PMID:
42599715
Bibliographic data and abstract were imported from PubMed on 15 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.